India Globalization Capital

POTOMAC, MD / ACCESS Newswire / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and addressing regional healthcare disparities.» Mehr auf accessnewswire.com

Squarepoint Ops LLC acquired a new stake in shares of IGC Pharma, Inc. (NYSEMKT:IGC – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 125,966 shares of the company’s stock, valued at approximately $42,000. Squarepoint Ops LLC owned 0.16% of IGC Pharma as of its most recent SEC filing. Separately, Geode Capital Management LLC boosted its holdings in IGC Pharma by 19.0% in the fourth quarter. Geode Capital Management LLC now owns 669,685 shares of the company’s stock worth $225,000 after purchasing an additional 106,716 shares during the period. 3.87% of the stock is currently owned by institutional investors. Analyst Ratings Changes Several equities analysts have recently issued reports on the stock. Alliance Global Partners reissued a “buy” rating and set a $3.50 price target on shares of IGC Pharma in a report on Thursday, March 6th. Ascendiant Capital Markets boosted their price target on shares of IGC Pharma from $4.00 to $4.25 and gave the company a “buy” rating in a report on Monday, February 24th. View Our Latest Stock Analysis on IGC IGC Pharma Stock Down 3.7% IGC opened at $0.31 on Wednesday. IGC Pharma, Inc. has a 1-year low of $0.25 and a 1-year high of $0.55. The company has a current ratio of 1.15, a quick ratio of 0.98 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $25.02 million, a price-to-earnings ratio of -2.85 and a beta of 1.48. The business has a 50 day moving average of $0.30 and a 200-day moving average of $0.32. About IGC Pharma (Free Report) IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. See Also Five stocks we like better than IGC Pharma What is a Death Cross in Stocks? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Quiet Period Expirations Explained Casey’s Surges on Strong Q4, More Gains Likely Ahead The 3 Best Fintech Stocks to Buy Now Government Mandate Sends eVTOL Stocks Flying» Mehr auf defenseworld.net

POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.» Mehr auf accessnewswire.com